SMMT ▲ +6.4% - Summit Therapeutics Inc. $SMMT - Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China Summit Therapeutics rose 6.4% after Akeso announced that ivonescimab monotherapy met its primary endpoint in the HARMONi-2 trial, showing statistically significant overall survival benefit versus pembrolizumab monotherapy in patients with PD-L1-positive advanced non-small cell lung cancer. The positive Phase 3 data for the company's lead candidate supports its potential as a competitive treatment option in a key oncology indication. 02-SEP-2026 05:42 PM ET